Gregorio Barilà

12PUBLICATIONS
47CO-AUTHORS
Predictive and prognostic markersAutoimmunityRegenerative medicine (incl. stem cells)Gene and molecular therapyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 18, 2026
Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study.

|Jun 26, 2025
NK-type large granular lymphocyte leukemia comes of age.

Gianpietro Semenzato, Antonella Teramo, Gregorio Barilà

|May 20, 2025
Prognostic stratification of standard risk multiple myeloma defined by revised international scoring system.

Gregorio Barilà, Laura Bonaldi, Annalisa Martines

|Mar 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

Fortunato Morabito, Enrica Antonia Martino, Monica Galli

|May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.

Enrica Antonia Martino, Salvatore Palmieri, Monica Galli

|Jan 18, 2024
The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders.

Gianpietro Semenzato, Giulia Calabretto, Antonella Teramo

Pageof 2

Frequent Collaborators

5 joint publications

Gianpietro Semenzato

4 joint publications

Vanessa Rebecca Gasparini

4 joint publications

Antonella Teramo

3 joint publications

Renato Zambello